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INTRODUCTION 
 
In 1876, Sir John S. Parry Wrote:  
 “….when one is called to a case of this kind, it is his duty to look 
upon his unhappy patient as inevitably doomed to die, unless he can by 
some active measure wrest her from the grave already yawning before 
her.” 
 
 The first recorded case of ectopic pregnancy is that of Albucasis in 
the 11th Century. The modern management of ectopic pregnancy is one of 
medicine’s greatest success stories. 
 
 The term Ectopic is derived from the Greek word “Ek and to-pos”, 
meaning “out of place or displaced”. Ectopic pregnancy is defined as the 
implantation of fertilized ovum or blastocyst anywhere other than in a 
normal uterine cavity. This includes tubal pregnancies and non-tubal 
pregnancies involving the ovary, cornual region of the uterus, 
rudimentary uterine horn, the abdominal cavity, and in the cervix. This 
abnormally implanted gestation grows and draws its blood supply from 
2 
 
the site of abnormal implantation. As the gestation enlarges, it creates the 
potential for organ rupture because only the uterine cavity is designed to 
expand and accommodate fetal development. Ectopic pregnancy can lead 
to massive hemorrhage, infertility, or death. 
 
MILESTONES IN EVOLUTION OF ECTOPIC 
PREGNANCY AND ITS MANAGEMENT: 
1535 – Begnegario – De – Capri described a case of secondary abdominal  
   pregnancy. 
1595 – Only recorded attempts of surgery by Jacob Noirus and Felic  
   Plater-1598. 
1681 – Rionis first described a pregnancy in rudimentary horn of uterus. 
1873 – Barnes introduced the term ectopic gestation. 
1882 – Spiegelberg introduced criteria to diagnose ovarian pregnancy. 
1883 – Robert Lawson Tait of Birmingham in London, pioneered a new  
   concept, timely surgical intervention could be life saving. 
1894 – Bussuere presented a case of unruptured ectopic gestation. 
1896 - Galabain presented a case of primary abdominal pregnancy. 
1911 – Rubin published criteria to diagnose cervical pregnancy.  
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1972 – Stepter and Edwards reported a case of tubal pregnancy following  
   In Vitro Fertilization. 
1982- Treatment of an interstitial ectopic pregnancy in a patient with a  
15day course of intramuscular methotrexates was reported by 
Tanaka et al. 
1991 – Stovall et al (University of Tennessee, Memphis, TN) concluded  
that methotrexate/ citrovorum treatment is safe and helps to 
preserve the reproductive potential. 
  
There is a decrease in the maternal mortality rate due to great 
improvement in anesthesia, blood transfusion and antibiotics. In the early 
half of the 20th Century, 200-400 deaths per 10,000 cases were attributed 
to ectopic pregnancy. In 1970, the Centre’s for Disease Control and 
Prevention (CDC) began to record the statistics regarding ectopic 
pregnancy, reporting 17,800 cases. By 1992, the number of ectopic 
pregnancies had increased to 108,800. Concurrently, however, the case-
fatality rate decreased from 35.5 deaths per 10,000 cases in 1970 to 2.6 
per 10,000 cases in 1992. With earlier diagnosis both maternal survival 
and conservation of reproductive capacity are enhanced. 
4 
 
AIM OF STUDY 
 
• To study the outcome of medically managed cases of unruptured 
tubal ectopic pregnancies using intramuscular methotrexate. 
• To study the association of outcome with the following parameters:  
1. Initial β – hCG levels 
2. Adnexal mass size 
3. Period of amenorrhea 
4. Presence or absence of cardiac activity 
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REVIEW OF LITERATURE 
 
Ectopic pregnancy is defined as implantation of fertilized ovum in 
a site other than the uterine cavity. 
 
 
Figure 1: Types of Ectopic Pregnancies 
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SITES OF IMPLANTATION 
TUBAL 
 About 95 percent of ectopic pregnancies are situated in the 
fallopian tube:  54% - ampulla; 24%- isthmus; 16% -frimbria ; 1.9 
percent in the interstitial region. When the ovum embedded in ampulla, 
several modes of termination are possible:  
1. Tubal mole 
2. Tubal abortion 
3. Tubal rupture or perforation 
4. Continuation of pregnancy till later months or even to term 
 
Figure 2: Blastocyst implanted in the fallopian tube 
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NON TUBAL 
• OVARIAN 
• CERVICAL  
• ABDOMINAL 
• HETEROTOPIC 
• INTERSTITIAL 
• INTERLIGAMENTOUS 
• CAESAREAN 
 
OVARIAN PREGNANCY :  
 Ectopic pregnancies implanted in the ovary is rare. 
 
Causes: Traditional risk factors for Tubal pregnancy are similar for 
ovarian pregnancy. Concurrent use of an intrauterine contraceptive device 
(IUD) seems to be inordinately associated with ovarian pregnancy.  
Spiegelberg’s (1878) Criteria for Pathological Diagnosis of Ovarian 
Pregnancy 
• The ipsilateral tube is intact and distinct from the ovary. 
• The ectopic pregnancy occupies the ovary. 
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• The ectopic pregnancy is connected by the uteroovarian ligament 
to the uterus. 
• Ovarian tissue can be demonstrated histologically in the placental 
tissue.  
 
Treatment : 
1. Ovarian cystectomy, Laparoscopic laser surgery,  
2. Methotrexate for unruptured ovarian pregnancy,  
3. Uncontrollable hemorrhage necessitates oophorectomy or salpingo 
– oophorectomy. 
 
CERVICAL PREGNANCY:  
 It is defined as the implantation of gestational tissue within the 
endocervical canal. 
Incidence: 1:8,600 to 1: 12,400 pregnancies. 
Cervix is rare but hazardous site for placental implantation because 
the trophoblast can penetrate through the cervical wall and into the 
uterine blood supply, resulting in profuse bleeding. 
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Causes : Previous induced abortion, Ashermann’s procedure, Previous 
caesarean delivery, DES exposure, Leiomyomata, In vitro fertialization 
and embryo transfer. 
Rubin’s (1911) criteria for diagnosis of cervical pregnancy: 
• Cervical glands must be present opposite the placental attachment 
site. 
•  A portion of or the entire placenta is located below either the 
entrance of the uterine vessels or below peritoneal reflection on the 
anteroposterior uterine surfaces. 
• Fetal elements must not be present in the uterine corpus. 
 
The Clinical Criteria for diagnosis of Cervical Pregnancy, as Defined 
by Paalman and Mcelin, include 
 
1. Amenorrhoea followed by painless uterine bleeding, 
2. Softened and disproportionately enlarged cervix(hour – glass – 
shaped uterus) 
3. Products of conception entirely confined within  and firmly 
attached to endocervical canal 
4. A snug internal os and 
5. A partially open external os. 
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Treatment : 
1. Evacuation of pregnancy by suction curettage after vascular 
ligation or lateral cervical suture placement to ligate lateral cervical 
vessels. 
2. Controlling hemorrhage with uterine packing, insertion of 
intracervical 30ml foley’s catheter to tamponade bleeding, 
angiographic arterial embolization. 
3. Treatment with systemic and local MTX either alone or in 
combination with cervical instrumentation (Timor – Tritsh et al 
1994). 
4. TVS guided injection of Kcl into gestational sac (Frates, 1994). 
5. Oral etoposide (Segma, 1990) or intravenous actinomycin – D 
(Brand et al, 1993). 
 
ABDOMINAL PREGNANCY 
Classified as      1.Primary abdominal pregnancy 
                           2. Secondary abdominal pregnancy 
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STUDDIFORD’S criteria for primary abdominal pregnancy: 
1. Presence of normal tubes and ovaries with no evidence of recent or 
past pregnancy. 
2. No evidence of uteroperitoneal fistula. 
3. The presence of a pregnancy related exclusively to the peritoneal 
surface and early enough to eliminate the possibility of secondary 
implantation after primary tubal nidation. 
 
DIAGNOSIS: 
 Physical examination, persistent abnormal fetal lie, abdominal 
tenderness, a displaced cervix, easy palpation of fetal parts, palpation of a 
uterus separate from the gestation, no uterine contractions after oxytocin 
infusion. Abdominal X-ray, Abdominal ultrasonogram, CT, MRI can be 
used to diagnose abdominal pregnancy. 
 
Treatment : 
Because the pregnancy can continue to term, maternal morbidity 
and mortality is very high, recommending surgical intervention. Perinatal 
mortality results from growth restriction and congenital anamolies      
(20-40%). 
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HETEROTOPIC PREGNANCY:  
  Heterotopic pregnancies were rare, with an incidenc of 1 in 
30,000. Currently because of assisted reproduction, incidence is likely to 
be 1 in 7000 overall, and following ovulation induction it may be as high 
as 1 in 900(Gaussner & associates 1990). The risk is as high as 2-3% 
among patients undergoing assisted reproduction. Causes of heterotopic 
pregnancy include ovulation induction, IVF-ET, Pelvic Inflammatory 
Disease. 
Surgery is the treatment of choice. MTX is contraindicated due to 
detrimental effects on the normal pregnancy. 
 
INTERSTITIAL PREGNANCY: 
 
Incidence : Accounts for 2-4% of all tubal gestations.   
 
 
Because of the proximity to the uterine and ovarian arteries, there 
is a risk of severe haemorrhage. 
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Treatment: Choice of treatment depends on the extent of trauma in the 
uterine wall and child bearing function of the patient. 
1. Cornual resection & repair of the defect either by laparotomy or 
laparoscopy. 
2. Medical treatment with local or systemic MTX. 
3. Local instillation of Kcl into ectopic gestational sac. 
4. Hysteroscopic resection of interstitial pregnancy. 
5. Hysterectomy. 
 
INTERLIGAMENTOUS PREGNANCY 
Incidence: 1 in 300 ectopic gestations 
Interligamentous pregnancy results from trophoblastic penetration 
of a tubal pregnancy through the tubal serosa and into the mesosalpinx, 
with secondary implantation between the leaves of the broad ligament.It 
also occurs if a uterine fistula develops between the endometrial cavity 
and the retroperitoneal space.  
The timing, extent and complications of surgery are similar to 
those of an abdominal pregnancy except that as the pregnancy is wholly 
extraperitoneal,torrential haemorrhage is less likely. 
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PERSISTANT ECTOPIC PREGNANCY 
Incidence: 3-20% 
 Persistent ectopic pregnancy occurs when a patient has undergone 
conservative surgery and viable trophoblastic tissue remains. 
 
Diagnosis 
1. Lack of fall, or plateuing of hCG level after conservative 
surgery. 
2. Initial measurement of serum hCG or progesterone 6 days post 
operatively and 3-day interval thereafter does not show any fall 
on the other hand may even increase. 
 
Risk factors 
1. Type of surgical procedure 
2. Initial HCG levels 
3. Duration of amenorrhea 
4. Size of ectopic pregnancy 
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Treatment:  
1. Medical therapy with methotrexate given as a single 
intramuscular injection in the dose of 50 mg/sq.m body surface 
area. 
2.  Surgical therapy consist of either repeat salpingostomy or 
salpingectomy.                                                                                                                                              
 
ETIOLOGY AND RISK FACTORS 
 
 Ectopic pregnancy most often is associated with risk factors 
leading to tubal damage and altered embryo transport.  
Table 1: Etiologies of Ectopic Pregnancy 
ANATOMIC HORMONAL EMBRYONIC 
Infection Premature ovulation  Altered implantation  
Inflammation Delayed ovulation  Blighted embryo 
IUD Hyperestrogenism  
Previous surgery Pergonal/clomid  
Prior induced abortion In Vitro fertilization  
Diethylstilbesterol   
Recurrent miscarriage   
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Table 2: Risk Factors for Ectopic Pregnancy 
RISK FACTORS ODDS RATIO 
Previous ectopic pregnancy 12.5 
Tubal corrective surgery 4 
Tubal Sterilization  9 
Intra uterine device 1-4.2 
Document tubal pathology 3.8-21 
Infertility >1year 2.5-3 
Assisted reproductive 
technology 
2-8 
Previous genital infections 3.4 
Multiple sexual partners 1.6-3.5 
Prior abortion 0.6-3 
Cigarette Smoking 1.7-4 
Prior cesarean delivery 1-2.1 
Age>40 years 2.9 
 
 
PATHOGENESIS: 
First, the conceptus and corpus luteum may be completely normal, 
but the fallopian tube is somehow blocked or damaged. In such cases the 
trophoblast proliferates normally and quickly invades the sub epithelial 
spaces. Secretion of   β -hCG and progesterone initially is similar to that 
of normal pregnancy and patient has no symptoms. As the trophoblast 
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begins to erode into small submucosal arterioles, hematoma formation 
occurs. This distends the tubal serosa and produces pelvic pain and an 
easily visualized bluish swelling within the tube. At this point the 
production of beta-hCG and progesterone usually begins to falter, there is 
insufficient support for the early corpus luteum, and patient starts having 
abnormal uterine bleeding. 
  
Second, the tube and corpus luteum may be normal, but the 
conceptus is abnormal (blighted ovum), creating a predispostition to 
ectopic nidation. In this case, initially serum beta-hCG and progesterone 
levels would be abnormally low early in course of gestation like a 
blighted ovum in Intra Uterine Pregnancy. 
 
Third, the conceptus and tube may be normal, but corpus luteum 
function is not. In this case initially normal beta-h CG levels can be 
expected, but progesterone will be abnormally low. 
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DIAGNOSIS 
 
 
1. Patient history 
2. Physical examination 
3. Endocrine markers 
4. Ultrasonography 
5. Doppler Ultrasound 
6. Culdocentesis 
7. Laparotomy 
8. Laparoscopy 
9. Histopathology 
Patient History and Physical Examination 
Table 3: Symptoms of Ectopic Gestation 
Symptoms % of Ectopics with Symptom 
Abdominal pain 95-100 
Amenorrhea 75-95 
Abnormal uterine bleeding  65-85 
Dizziness 20-35 
Urge to defecate 5-15 
Pregnancy symptoms 10-25 
Nausea 15 
 
19 
 
Table 4: SIGNS OF ECTOPIC PREGNANCY 
Signs Patients with sign % 
Adnexal tenderness                                       75-90 
Abdominal tenderness                                     80-95 
Adnexal mass                                                    50 
Uterine enlargement                                      20-30 
Orthostatic changes                                          10-15 
Fever                                                           5-10 
 
Multimodality Diagnosis 
1) Serial Beta- hCG Assays: Human chorionic gonadotropin is a 
glycoprotein produced by syncytiotrophoblast. The serum beta – hCG 
radioimmunoassay is the gold standard for evaluating trophoblast 
activity. In ectopic pregnancy, the serum beta-hCG tends to be lower  
than with a viable IUP given the same gestational age. For patients 
with tubal pregnancies, higher serum beta-hCG levels correlate with 
the tubes being ruptured, the size of eccyecis, and volume of 
hemoperitoneum. It is detected in the serum 8 days after the 
luteinizing hormone (LH) surge and in the urine 13 days after 
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ovulation around the time of implantation. Most qualitative blood 
pregnancy tests are considered positive with an HCG level of 
30mlU/ml, 14 days post conception. With a robust uterine pregnancy, 
serum b-hCG should increase atleast 66% every 48hours. Beta-hCG 
doubles every two days in a normal IUP. A 66% rise in the beta-hCG 
level over 48 hrs (85% confidence level) represents the lower limit of 
normal values for viable intrauterine pregnancy.  15% of healthy 
intrauterine pregnancies do not increase by 65% and that 13% of all 
ectopic gestations have normally rising beta – hCG  of atleast 65% in 
48 hours.The beta-hCG pattern that is most predictive of ectopic 
pregnancy is one that has reached a plateau ( a doubling time of more 
than 7 days). For falling levels, a half life a less that 1.4 days is rarely 
associated with ectopic pregnancy, where as a half life more than 7 
days is most predictive of ectopic pregnancy. 
 
2) CA-125:   CA-125 has been increased in women with epithelial 
ovarian cancer, acute pelvic inflammatory disease, and early normal 
pregnancy. In a prospective single blind and controlled study done by 
Erdal et al found that in intact tubal pregnancies, the increase of CA-
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125 levels in the serial measurements could be a supplementary test 
for an early diagnosis of tubal rupture in patients with expectant or 
medical management. 
 
3) PAPP-A: The Pregnancy associated plasma protein – A Sjoberg 
measured serum PAPP-A concentrations in 164 patients presented to 
gynaecologic emergency services: 124 women had EP and 40 had 
intrauterine abortions. The PAPP-A levels in 136 women with normal 
IUP were compared with those of 460 non-pregnant women. Serum 
PAPP-A levels were lower in the EP and intrauterine abortion groups 
compared to the normal pregnancy group; they were undetectable in 
82% of the EP group and 55% of the intrauterine abortion group. 
 
4) Serum Progesterone: is used by Stovall(1992) to diagnosis ectopic 
pregnancy when serum b-hCG and sonographic findings are 
inconclusive.There is minimal variation in serum progesterone levels 
between 5 and 10 weeks gestation, thus a single value is sufficient. 
Mol (1998) performed  a meta-analysis of 22 studies to assess the 
accuracy of single serum progesterone measurement to differentiate 
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ectopic from uterine pregnancy. The meta-analysis revealed that low 
levels of serum progesterone (<5ng/ml) could be used to correctly 
diagnose pregnancy failure, but cannot differentiate between an 
ectopic and uterine pregnancy.  
 
5) Pregnanediol-3 Alpha-Glucuronide: Sauer and coworkers reported 
that a rapid enzyme immunoassay for levels for urinary 
pregnannediol-3 alpha-glucuronide correlated well with serum 
progesterone levels and were also consistently below expected levels 
in 60 patients with ectopic pregnancies. 
 
6) Relaxin 
 
7) Maternal Serum Alpha Fetoprotien and Cell Free Fetal DNA  
 
8) C – Reactive Protein 
 
 
9) VGEF:  VGEF is a potent angiogenic factor that acts as a modulator 
of vascular growth, remodeling, and permeability in the endometrium, 
decidua, and trophoblast, as well as during vascular development in 
23 
 
the embryo, all of which are crucial process related to normal 
implantation and placentation. Felemban et al concluded that VEGF 
concentrations are higer in women with EP than in those with normal 
and arrested IUP. Daponte et al described higher serum VEGF 
concentrations in women with EP (median pg/ml) than in those with 
abnormal intrauterine pregnancy (median 107.2pg/ml) (P<0.001). 
 
10) Serum Creatine Kinase: The lack of a sub mucosal layer in the 
fallopian tube allows zygote to penetrate the epithelium and lay 
next to the muscular layer in tubal pregnancies. The trophoblast 
usually invades the muscle layer and maternal blood vessels are 
eroded, allowing muscle cell products such as CK to enter the 
circulation; therefore, increased serum CK levels are normal 
during EP. Katsikis et al studied 40 women with EP 20 with 
intrauterine abortive gestation and 20 normal pregnant women 
(controls). Total serum CK levels were measured at the time of 
presentation and 24 hours after surgery. Women with EP had 
significantly higher CK concentrations compared to women with 
intrauterine abortive pregnancies and controls. 
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11) Pregnancy Specific B1 Glycoprotein (Shwangerschaft 
Protein):  
 
12) Renin: 
 
13) Inhibin-A:  
 
Sonography 
 High resolution sonography has revolutionized the clinical 
management of women with ectopic pregnancy. The imaging modality of 
choice for the diagnosis of ectopic pregnancy is Transvaginal 
sonography(TVS) with overall reported sensitivities of >90%. In the large 
study of more than 1200 patients by Barnhart et al, 78.8% of patients 
were diagnosed definitely at the initial visit using an algorithm that 
included the use of USG along with serum beta-hCG levels above the 
discriminatory zone. 
 According to this study, if the patient’s serum beta-hCG level was 
above the established discriminatory zone at initial presentation and an 
intrauterine   sac was not identified, an operative approach involving 
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curettage and possible operative laparoscopy was used to diagnose 
ectopic pregnancy. Combined transvaginal ultrasonograpy and serial 
quantitative beta-hCG measurements are approximately 96% sensitive 
and 97% specific for diagnosing ectopic pregnancy. Therefore, 
transvaginal ultrosonography followed by quantitative beta-hCG testing 
is the optimal and most cost-effective strategy for diagnosing ectopic 
pregnancy. It is reported that using TAS, an intra-uterine sac can be 
visualized when the serum beta-hCG is >6500 IU/L. However with a 
TVS an intrauterine sac should be visualized with serum beta-hCG as low 
as 1000 IU/L. The use of TVS in the diagnosis of ectopic pregnancy has 
become widely accepted and practiced. Transvaginal ultrasonography has 
transformed the assessment of problems in early pregnancy. In 
fact,Condous, upholds that “transabdominal ultrasonography is outdated 
modality which is not diagnostic of ectopic pregnancy and should no 
longer be used”. Majority of studies show TVS to be an accurate 
diagnostic test for ectopic pregnancy with a high sensitivity of 87-99% 
and specificity of 94-99%. Shalev and colleagues found that the use of 
TVS in the diagnosis of an ectopic pregnancy has a sensitivity of 87%, 
specificity of 94%, and positive predictive value of 92.5%. Another study 
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gave a sensitivity of 93%, specificity of 99%, and positive predictive 
value of 98%, and when a TVS finding of an adnexal mass was combined 
with serum beta-hCG, this increased the sensitivity of 97%, with 
equivalent specificity and positive predictive value. 
 To make the diagnosis, an ectopic mass should be seen in adnexa 
separate to the ovary and an empty endometrial cavity. The following 
may be visualized: 
1. An inhomogeneous adnexal mass. 
2. An empty extra – uterine sac with a hyper-echoic ring or bagel 
ring.  
3. A yolksac and /or a fetalpole with or without cardiac activity in the 
extra-uterine sac. 
Sometimes there are no conclusive adnexal findings, and the diagnosis 
of ectopic pregnancy may be based on the other ultrasound features, such 
as hemoperitoneum, hematosalpinx, and free fluid in the peritoneum or 
the pelvis, for example, in the pouch of Douglas. 
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Discriminatory Zone: 
 In the management of suspected ectopic pregnancy there is a serum 
hCG level at which it is assumed that all viable intrauterine pregnancies 
will be visualized by transvaginal ultrasound. This is referred to as the 
discriminatory zone.  
 When serum hCG levels are below the discriminatory zone (<1000 
IU) and there is no pregnancy (intra-or extra uterine) visible on 
transvaginal ultrasound scan, the pregnancy can be described as being of 
unknown location. The concept of a discriminatory zone has limitations. 
Levels of hCG of 1000 IU/L, 1500 IU/L and 2000 IU/L have been used 
as discriminatory levels. 
 
Table 5: Transvaginal Ultrasound Findings in Ectopic Pregnancy  
Finding LR* 
Ectopic cardiac activity >100(diagnostic) 
Ectopic gestational sac 23 
Ectopic mass and fluid in pouch of Douglas 9.9 
Fluid in pouch of Douglas 4.4 
Ectopic mass 3.6 
No intrauterine gestational sac 2.2 
Normal adenexal region 0.55 
Intrauterine gestational sac 0.07 
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 LR = likelihood ratio. 
       *_An LR > 5 - moderately strong evidence  
                  LR > 10 - strong evidence  
      LR < 0.1 is strong evidence against ectopic gestation.  
 
DOPPLER ULTRASOUND: 
       The waveform in the uterine arteries in the nongravid state in the first 
trimester of pregnancy shows a high resistance (little or no flow), low 
velocity pattern. Conversely a high velocity, low resistance signal is 
localized to the area of developing placentation. This pattern seen near 
the endometrium is associated with normal and abnormal intrauterine 
pregnancies and is termed peritrophoblastic flow.The combined use of 
Doppler and two dimensional imaging allows the differentiation of 
pseudogestational sacs and true intrauterine gestational sacs. It also 
improves the diagnostic sensitivity for individual diagnosis from 71% to 
87% for ectopic pregnancy, from 24% to 59% for failed intrauterine 
pregnancy and from 90% to 99% for normal intrauterine pregnancy. With 
transvaginal colour Doppler imaging, placental blood flow within the 
periphery of the complex adnexal mass-the ring of fire is seen.   
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CULDOCENTESIS 
         Historically, culdocentesis was an easy bedside test used to 
diagnose hemoperitoneum.With the use of hCG testing and transvaginal 
ultrasound, culdocentesis is rarely indicated. 
 
ENDOMETRIAL SAMPLING 
 If the patient is bleeding excessively and requires a D & C, the 
removed products are sent for histopathological examination. Decidua 
without chorionic villi although suggests but does not confirm the 
diagnosis of ectopic pregnancy as these findings occur with spontaneous 
abortions as well. 
 
LAPAROSCOPY 
 Laparoscopy facilities early diagnosis of ectopic pregnancy. It has 
reduced the clinical error in diagnosing an ectopic pregnancy to less than 
4% of cases and the simpler technique has limited the need for 
laparotomy. 
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Indications 
1. When unruptured ectopic is suspected but patient has signs of 
intraperitoneal bleeding. 
2. When patient has beta-hCG levels less than 6500 mIU/ml on a 
negative ultrasound. 
3. Patients who have less than 66% increase in beta-hCG over 48 hrs. 
 
MANAGEMENT 
1. Expectant management 
2. Medical treatment 
3. Salpingocentesis 
4. Surgical treatment. 
 
EXPECTANT MANAGEMENT 
 Expectant management is between 88 & 96 percent effective in 
managing ectopic pregnancy when the initial β-hCG values<200IU/L.  
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Criteria 
1. Falling HCG titre 
2. Ectopic pregnancy definitely in the tube 
3. No significant bleeding 
4. No evidence of rupture 
5. Ectopic mass no larger than 3.5cm in greatest diameter 
 
Expectant management included the monitoring of clinical symptoms, 
HCG titers, and ultrasonographic findings. Approximately one fourth of 
patients presenting with ectopic pregnancy can be managed expectantly 
and 70% of this select group will avoid surgery and experience successful 
outcomes. Success with expectant management decreases with rising 
HCG levels. Best results are achieved when initial HCG levels are below 
200IU/L. An argument could be made that minimal side effects of 
methotrexate make it preferable to a potentially prolonged surveillance 
and associated patient anxiety. 
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MEDICAL TREATMENT 
 Medical therapy is preferred by most, if feasible. In the United 
States, during 2002-2007, the percentage of patients treated with 
methotrexate increased from 11% to 35%.Comparison of medical and 
surgical treatment of small intact extrauterine pregnancies also revealed 
similar success and subsequent spontaneous pregnancy rates in a 
prospective randomized trial done by Moeller et al. 
 
Methotrexate 
 Methotrexate formerly known as amethopterin, is an antimetabolite 
drug that inhibits dihydrofolate reductase-blocking the conversion of 
dihydrofolic acid to tetrahydrofolic acid which is an essential coenzyme 
required for 1 carbon transfer reactions in de novo purine synthesis. 
Methotrexate has cell cycle specific action – kills cells in S phase; 
primarly inhibits DNA synthesis. 
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Table 6: Case Series using Expectant Management for Treatment of  
Ectopic pregnancy 
 
Study Year Patients Success Tubal Patency 
Intrauterine 
Pregnancy 
Recurrent 
Ectopic 
Pregnancy 
Land 1955 119 68(57) NR 32/43 11/43 
Mashiach et al 1982 5 4(80) 1/1 NR NR 
Carp et al 1986 14 11(79) 5/5 3/5 1/5 
Adoni et al 1986 11 11(100) NR NR        NR 
Dericks Tan et 
al 
1987 12 12(100) NR NR NR 
Garcia et al 1987 13      12(92) 7/10 3/3 0/3 
Fernandez et al 1988 14 9(64) NR NR NR 
Seuer et al 1987 
1989 
10 10(100) NR NR NR 
Makinen et al 1990 35 27(82) NR NR NR 
Carson et al 1991 8 5 NR NR NR 
Korhonen et al 1994 118 77(65) NR NR NR 
Shalev et al 1995 60 28(47)49(73) NR NR NR 
Brio et al 1995 67 49(73) NR NR NR 
Total  198 137(69) 13/16 38/51 12/51 
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Methotrexate: Pharmacokinetics 
 Methotrexate is a weak dicarboxylic acid with pKa 4.8 and 5.5, and 
thus it is mostly ionized at physiologic pH. Oral absorption is saturatable 
and thus does-dependent, with doses less than 40 mg/m2 having 42% 
bioavailability and doses greater than 40 mg/m2 only 18%. Mean oral 
bioavailability is 33% (13-76% range), and there is no clear benefit to 
subdividing an oral dose. Mean intramuscular bioavailability is 76% 
Methotrexate is metabolized by intestinal bacterial to the inactive 
metabolic 4-amino-4-deoxy-N-methylpteroic acid (DAMPA) and 
accounts for less than 5 % loss of the oral dose. Factors that decrease 
absorption include food, oral non-absorbable antibiotics (e.g. 
vancomycin, neomycin, and bacitracin), and more rapid transit through 
the gastrointestinal tract (GI) such as diarrhea, while slower transit time 
in the GI tract from constipation will increase absorption. 
 
Treatment and side effects associated with MTX: Methotrexate is a 
highly tertogenic drug and categorized in Pregnancy Category X by the 
FDA  
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Treatment effects: 
• Increase in ectopic mass by Ultrasound 
• Increase in HCG during initial therapy 
• Vaginal bleeding or spotting 
• Abdominal pain (separation pain) 
 
Drug side effects: 
• Nausea, Vomiting 
• Stomatitis 
• Dizziness 
• Gastic distress 
• Serve neutropenia(rare) 
• Reversible alopecia(rare) 
• Pneumonitis (rare) 
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Table 7: Success Rate -Methotrexate Therapy  
 at Various Baseline Beta-hCG Level. 
Initial beta-hCG level (mIU/mL) Success rate 
(%) 
Less than 1,000(1,000 IU per L) 98 
1,000 to 1,999(1,000 to 1,999IU per L) 93 
2,000 to 4,999(2,000 to 4,999 IU per L) 92 
5,000 to 9,999(5,000 to 9,999 IU per L) 87 
10,000 to 14,999(10,000 to 14,999 IU per L) 82 
15,000 or greater(15,000 or greater IU per L) 68 
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Table 8: Case Series using Methotrexate as Primary  
Treatment for Ectopic Pregnancy 
Study Year 
No. of 
Patients 
Success Dosage 
Patency 
Rate 
Laparotomy 
Needed 
Toxicity 
 
Myazaki et al 
 
1983 
 
18 
 
7(88) 
 
30-60 MG I/M 
 
4/5(80) 
 
1 
 
- 
 
Ory et al 
 
1986 
 
7 
 
6(86) 
1MG/KG 
4days IV 
 
4/7(57) 
 
1 
 
5 
 
Goldstein 
 
1986 
 
7 
 
6(86) 1MG/KG 
4days IM 
 
4/4(100) 
 
1 
 
0 
 
6 
 
6(100) 200MG / M2 
 
- 
 
 
0 
 
0 
 
Sauer et al 
 
1987 
 
21 
 
20(95) 
1MG/KG 
4days IM 
 
15/20(75) 
 
1 
 
5 
 
Ichino et al 
 
1987 
 
23 
 
22(96) 
0.4 MG/KG 
5days IM 
 
10/19(53) 
 
1 
 
5 
 
Stovall et al 
 
1989 
 
36 
 
34(94) 
1MG/KG 
1-5 days IM 
 
- 
 
2 
 
3 
 
TOTAL 
  
108 
 
101(94) 
 
- 
 
43/62(70) 
 
7 
 
18 
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CRITERIA FOR PATIENT SELECTION 
1. Patient is healthy, hemodynamically stable, reliable and complaint. 
2. Ultrasonography should fail to find an intrauterine pregnancy, and 
uterine curettage should fail to obtain villi. 
3. Ectopic pregnancy should measure less than 4 cm in its greatest 
diameter 
4. HCG titers >10,000 IU/L and presence of fetal heart rate are 
relative contraindications. However even patient with fetal cardiac 
activity, success rate of 87% has been reported. 
 
Single Dose Regimen of Methotrexate for Treatment of Ectopic 
Pregnancy 
The average success rates for the single-dosage regimen are 
reported to be from 88-94%. In a study by Stoval and Ling, 113 patients 
(94%) were treated successfully, 4 (3.3%) of whom needed a second 
dose. 
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• DAY 1 : Baseline Studies, 
               β-hCG 
               Methotrexate 1mg/kg i.m 
• DAY 4 : β -hCG Titer 
• DAY 7 : β -hCG Titer 
• Weekly : β -hCG Titer becomes Negative 
 
In a prospective review of 110 patients, conducted by Thia et al 
from Aug 2003 to Oct 2006, 87(79.1%) patients were treated 
successfully with single dose of MTX following the above regimen. 
6(5.4%) required second dose and 16(14.5%) patients underwent 
surgery and only one patient defaulted on followup. In this cohort 
study, there was no major side effect detected.  Mucositis (19%) and 
abdominal pain (28 %) were minor side effects. 
 In a prospective interventional study done on 11 patients by 
Merisio et al from Dec 2002 to Apr 2003, single dose MTX were 
treated for 10(90%)  whereas 1(10%) patient required second dose. 
None of the patients had to undergo laparotomy. 
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In a retrospective cohort study done by Mamdoh et al, Ectopic 
pregnancy was diagnosed for 70 women and were treated with single 
dose MTX (50mg/kg).After a single dose, 66(94%) patients 
experienced ectopic resolution, 3(4%) patients needed a second dose 
of MTX, and 1(1.5%) patient has a subsequent tubal rupture. 
  
By the 3rd day, there is increase in the beta-hCG levels and is not 
significant. A decrease in the beta-hCG levels of at least 15% from 
days four to seven post injection shows a successful medical 
treatment. A systemic review conducted by Menon et al, supports that 
when the initial beta-hCG is above 5,000 mIU/mL, there is an 
increase in failure of medical treatment with single-dose 
methotrexate. So, above this β-hCG level, Methotrexate should be 
used with caution. 
 
A hybrid protocol, involving 2 equal doses of methotrexate (50 mg 
/m2) given on days I and 4 without the use of leucovorin has been 
shown to be an effective and convenient alternative to the existing 
regimens. Success rates were 81.5% for expectant management, 90% 
for medical management, and 91% for surgical management. 
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Methotrexate -Multiple Dose Regimen  
• DAY 1 : Methotrexate 1.0mg/kg i.m 
Hb, TC/DC, Platelet count, RFT/LFT, 
Serum beta-hCG. 
• DAY 2 : Folinic Acid 0.1 mg/kg i.m. 
• DAY 3 : Methotrexate 1.0mg/kg i.m 
Beta-hCG Titer 
• DAY 4 : Leucovorin 0.1 mg/kg i.m  
• DAY 5 : Methotrexate 1.0mg/kg i.m. 
Beta-hCG Titer 
• DAY 6 : Leucovorin 0.1 mg/kg i.m  
 
•  DAY 7 :  Methotrexate 1.0mg/kg i.m. 
Beta-hCG Titer           
• DAY 8 : Folinic Acid 0.1 mg/kg i.m  
Complete blood and platelet counts, liver and 
renal function tests 
• WEEKLY : Beta-hCG Titer Till Negative or <5 mIU/ml 
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• Treatment is declined when a decline of >15% is observed in two 
consecutive daily counts, or after 4 doses of methotrexate. 
• Weekly titers are done and second course of treatment is 
requirement if beta-hCG titers plateau or rise. 
 
In a 2003 meta-analysis , single-dose regimen were given for 20 
patients, and  multiple-dose regimen for 6 patients.There was fewer side 
effects with single dose regimen but was  less effective. The success rate 
was 88% compared with the multiple-dose regimen’s 93% success rate. 
The overall success rate was 89% regardless of the protocol. 
 
A prospective randomized trial conducted by Guvendag et al showed 
that multiple dose methotrexate regimen for the treatment of unruptured 
tubal ectopic pregnancy is not more effective than a single dose one. In 
addition, multiple doses may cause more side-effects, but the time for 
beta-hCG levels to fall below 5 mUI/mL is shorter. 
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SALPINGOCENTESIS 
It is a technique in which methotrexate, prostaglandin f2 alpha, 
potassium chloride is directly injected into the gestational sac within the 
tubal lumen to induce resorption or absorption. In 1987 Feichtinger and 
Kemeter reported the first successful treatment of ectopic pregnancy by 
the injection of methotrexate. 
 
Prostaglandins 
 Prostaglandins cause strong tubal muscular contractions and are 
local vasoconstrictors. Due to side effects like vomiting and abdominal 
cramps attempts using prostaglandin E2 injections directly into ectopic 
gestations were abandoned. Direct injections of prostaglandin f2 alpha 
into the affected tube and the ovary containing the corpus luteum was 
successful in 24 (92%) of 26 patients and Husslein et l reported and 84% 
success rate in 152 patients in eight centers in Austria. Lindblom and 
associates treated 9 women laparoscopically directed  transtubal 
injections of prostaglandin f2 alpha. Complications like ventricular 
arrhythmias, transitory hypertension with pulmonary edema were 
experienced, which were attributed to concomitant injection of PG f2 
alpha into the ovary. 
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Hyperosmolar Gulcose 
 Hyperosmolar glucose has been injected either laparoscopically or  
by transvaginal ultrasound guidance. 
 
Potassium Chloride 
Potassium chloride has been used for salpingocentesis. Robertson 
and associates injected a 20% potassium chloride solution into three tubal 
gestations. One case included a heterotopic pregnancy with co-existing 
intrauterine and cornual pregnancies. The authors were successful in 
resorption of cornual pregnancy without disturbing the intra uterine 
pregnancy. The other two patients did not have successful treatment and 
ultimately required laparotomy. 
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SURGICAL TREATMENT OF ECTOPIC PREGNANCY 
Salpingotomy Versus Salpingectomy 
 In the presence of a healthy contra lateral tube there is no clear 
evidence that salpingotomy should be used in preference to 
salpingectomy.  
 
Laparoscopy 
        In the haemodymaically stable patient, laparoscopic approach to the 
surgical management of ectopic pregnancy, is preferable to an open 
approach. 
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MATERIALS AND METHODS 
 All patients admitted to Institute of Obstetrics and Gynecology, 
with diagnosis of unruptured ectopic pregnancy managed medically 
between August 2011 and July 2012 were included in the study. The 
diagnosis of tubal pregnancy was made using both Transvaginal 
Sonography (TVS) and measurement of β-hCG level. Ectopic pregnancy 
was diagnosed when adnexal mass or extra uterine tubal gestational sac 
without intrauterine gestation was observed with TVS and when patients 
had inappropriately rising β-hCG levels. Patients who were 
hemodynamically unstable and who refused medical treatment with MTX 
and close follow-up were treated surgically. 
The patients who were managed medically with methotrexate were 
categorized into 5 groups for follow up based on initial β-hCG levels. 
(<2500) mIU/ml, (2500-5000) m IU/ml,and (7500-10000) m IU/ml . 
 Patients with very low β-hCG levels (<200 m IU/ml) were 
managed expectantly. 
 Single dose methotrexate regimen was followed for patients with 
β-hCG levels ranging from 200m IU/ml to 6984 m IU/ml. 
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Multiple dose methotrexate regimen was followed for patients with 
β-hCG levels more than 7500 m IU/ml. 
 Before treatment with methotrexate, patients were counseled about 
the benefits and risk of treatment, the expected course and duration of 
treatment, and the importance of follow-up. Blood grouping and typing 
was done for all the patients and Anti-D immunoglobulin (2501U or 50 
micrograms) administered to all Rh Negative mothers. All patients gave 
their informed consent before beginning the treatment. 
Inclusion Criteria 
• Patients who came with amenorrhea , abdominal pain, bleeding or 
spotting P/V and were diagnosed to have ectopic pregnancy after 
doing: 
1. Urine Pregnancy Test 
2. Trans vaginal sonography 
3. Serum β-hCG Levels 
• Hemodynamically stable patients without active bleeding or signs 
of hemoperitoneum. 
• Patients desiring future fertility 
• Patients willing for follow up care 
• No contraindication to MTX therapy 
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Exclusion Criteria 
• Hemoperitoneum or hemodynamically unstable patients 
• Contraindication to MTX therapy 
1. Breastfeeding 
2. Overt evidence of immunodeficiency 
3. Alcoholism /other chronic liver disease 
4. Pre existing blood dyscrasias 
5. Known sensitivity to methotrexate 
6. Active pulmonary disease 
7. Peptic ulcer disease 
8. Any chronic renal disorder 
Single Dose Regimen 
           After doing Hemoglobin level, Total Count/Differential Count, 
Platelet Count, Renal function tests, Liver function tests and Serum β-
hCG , on DAY 1,single intramuscular dose (1mg/kg) of methotrexate was 
given. On Day four and seven after the injection, β-hCG levels were 
measured. Patients received a repeat injection of MTX on Day 7 if their 
β-hCG levels failed to decline by atleast 15% between Day four and 
seven, and the protocol was restarted as Day 1.If the repeat β-hCG level 
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on Day 7 showed more than 15% fall when compared to Day 4, weekly 
follow up was done till levels <5mIU/ml. A successful response to MTX 
was defined as the resolution if the β-hCG level < 5mIU/mL. However, 
patients who required second dose of MTX due to inadequate fall in β-
hCG levels by Day 7 were considered as failure of single dose regimen 
but successful medical treatment. With signs of tubal rupture, surgery 
was done. 
             All continuous variables are expressed as the mean ±SD. For 
statistical analysis, T-test and Chi-square test were used. 
 
Multiple Dose Regimen 
As in single dose regimen, these patients also underwent 
investigations, namely Hemoglobin levels, Total Count/Differential 
Count, Platelet count,Kidney function tests,LFT and serum β-hCG levels. 
Inj. Methotrexate (1 mg/kg) intramuscular was given on DAY 1, 3, 5 & 7 
of the protocol followed by Inj. Leucovorin (0.1 mg/kg) on DAY 2,4,6 & 
8.Serum β-hCG levels were repeated every alternate day from Day 3 
onwards. 
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Complete blood and platelet count along with renal and liver 
function tests were repeated at the end of protocol to see any adverse 
effects of the drug. Weekly titres of β-hCG were done till they were <5 m 
IU/ml. However treatment was declined when a decline of >15% was 
observed in two consecutive counts of serum β-hCG after Day 3, or after 
completion of four dose of methotrexate (MTX). These patients were also 
followed up with weekly titers of β-hCG. 
 
Expectant Management 
 With serial β-hCG measurements twice weekly was done to ensure 
a rapidly decreasing β-hCG level and transvaginal ultrasound 
examinations weekly to see the decrease in the size of adnexal mass by 7 
days. Thereafter, weekly β-hCG and transvaginal ultrasound 
examinations were advised till serum β-hCG levels were < 5 mIU/ml. 
 
 
 
 
 OBSERVATIONS AND RESULTS
 Total number of cases of ectopic tubal pregnancy from August 
2011 to July 2012 were 119. Out of these 119 cases , 39 were managed 
medically during the same period (32.7%).
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UNDERWENT SURGERY
PREGNANCIES
 
 
 AGE DISTRIBUTION
    
     Age of patients in the study range from 19 to 36 years with mean 
age of 27.3 years ± 5.50 SD. The age distribution was as follows:
 
Table  9:Age Distribution(n=39)
 
AGE GROUP
< 20 
21-25 
26-30 
31-35 
36-40 
Total 
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: 
 
 n=39 % 
3 7.7 
16 41.0 
7 17.9 
11 28.2 
2 5.1 
39 100.0 
21-25 26-30 31-35 36-40
AGE IN YEARS
 
 
 GRAVIDITY DISTRIBUTION
 
 Among the patients studied, 21% were 
second gravidas. The gravidity distribution in the groups was as follows
 
         Table 10: Gravidity Distribution
 
GRAVIDITY
Primi gravida
G2 
G3 
G4 
Total 
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: 
primigravida and 10% were 
 
 n=39 % 
 21 53.8 
10 25.6 
5 12.8 
3 7.7 
39 100.0 
Primi gravida G2 G3 G4
: 
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ASSOCIATED RISK FACTORS FOR ECTOPIC PREGNANCY: 
 
 Various associated factors which increase of risk of ectopic 
pregnancies were studied in the 39 cases. 17 out of total 39 had an 
associated risk factors and the commonest risk factor was found to be 
Medical termination of pregnancy(17.9%) followed by previous LSCS 
(12.8%). 
 
The risk factors was as follows: 
 
Table 11: Associated Risk Factors For Ectopic Pregnancy 
 
RISK FACTOR n=17 % 
H/O MTP 7 17.9 
H/O previous LSCS 5 12.8 
H/O Past use of IUCD’S 2 5.1 
H/O Previous ectopic 
pregnancies 
3 7.7 
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GESTATIONAL AGE DISTRIBUTION
 
 Among the patients studied gestation
with mean gestational age of 48.2 days ±
patients at gestational age between 43 to 56 days. i.e 56.4%. The 
gestational age distribution is as follows:
Table 12: Gestational Age:
 
 
GESTATIONAL AGE
28-42 days 
43-56 days 
57-70 days 
Total 
56 
43-56 days 57-70 days
GESTATIONAL AGE IN DAYS
DISTRIBUTION
: 
al ranged from 28 to 70
 9.03 SD. Maximum n
 
 
 
n=39 % 
11 28.2 
22 56.4 
6 15.4 
39 100.0 
 days 
umber of 
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β-hCG LEVELS AT PRESENTATION: 
 
 In the study group, the distribution of β-hCG levels were studied. 
The maximum number of patients had their β-hCG levels between 200-
2500 m IU/ml. The distribution of β-hCG levels was as follows: 
 
 
Table 13: Β-hCG Levels At Presentation 
 
 
 
 
 
 
 
  
Initial β-hCG levels 
(m IU/ml) n=39 % 
 < 200 5 13 
201-2500 18 46.8 
2501 -5000 4 10.4 
5001-7500 7 17.9 
7501-10000 5 13 
Total 39 100.0 
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ADNEXAL MASS SIZE AT PRESENTATION: 
 
 Maximum number of patients i.e 56.4% had their adnexal mass 
size between 2-3 cms.The distribution of adnexal mass size at 
presentation was as follows: 
 
 
 Table 14: Adnexal Mass Size at Presentation 
 
 
Adnexal Mass Size 
 
 
n=39 Percent 
0-1cm 3 7.7 
1-2cm 13 33.3 
2-3cm 22 56.4 
> 3cm 1 2.6 
Total 39 100.0 
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METHOTREXATE REGIMEN DISTRIBUTION 
  
Out of 39 patients 29 were managed with single dose of 
intramuscular methotrexate injection, 1 mg/kg, where as 5 patients were 
given multiple doses of methotrexate as they presented with β-hCG level 
more than 7500 mIU/ml. 5 patients were not given any dose of 
methotrexate as they presented with very low levels of β-hCG level i.e 
<200 m IU/ml. The distribution of various methotrexate regimen was as 
follows: 
 
Table 15: Methotrexate Regimen Distribution 
 
 
Medical treatment with 
methotrexate 
n Percent 
 
Expected management 
5 12.8 
 
Single Dose Regimen 
29 74.4 
 
Multiple Dose Regimen 
5 12.8 
 
Total 39 100.0 
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SINGLE DOSE REGIMEN-OUTCOME OF TREATMENT 
 
Of the 29 patients treated with single dose regimen 22(76%) 
resolved with single dose, 3(10.3%) required repeat second dose, and 
4(13.7%) were managed surgically before day 7 due to severe pain 
abdomen or evidence of hemoperitoneum. The outcome of treatment was 
as follows: 
 
Table 16: Outcome Of Treatment-Single Dose Regimen 
 
 
OUTCOME OF 
TREATMENT n=29 % 
Resolved with single dose 22 76 
Required repeat second dose 3 10.3 
Underwent surgery 
 
4 13.7 
Total 29 100 
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FINAL OUTCOME IN ASSOCIATION WITH INITIAL β-hCG 
LEVELS: 
           Among the patients given single dose methotrexate, 18 had β-hCG 
levels than 2500mIU/ml, 4 had levels between 2500-5000 m IU/ml and 3 
patients had β-hCG levels from 5000-7500 mIU/ml. Among the 5 patients 
treated with multiple dose regimen, 5 patients presented with β-hCG levels 
between 7500-10000 mIU/ml. The association of outcome with initial β-hCG 
levels is as follows (p value<0.05 significant): 
             
Table 17:Day1 hCG levels gps * OUTCOME * 
Methrotrexate regimen 
  
Methotrexate regimen 
OUTCOME 
Resolved % 
Underwent 
surgery 
% Total 
Expectant 
Management 
Day1 hCG level 
gps 
less than 200 5 100% - - 5 
  
  
 
 
  
  
 
 
Total 5    5 
Single Dose 
Regimen 
 
Day1 hCG level 
gps 
201-2500 18 62% 0 - 18 
2501-5000 4 13.7% 0 - 4 
5001-7500 3 10.3% 4 13.7% 7 
     
 
Total 25  4  29 
Multiple Dose 
regimen 
 
Day1 hCG level 
gps 
7501-10000 2 40% 3 60% 5 
Total 2  3  5 
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     P value<0.05, hence statistically significant association was found 
between initial β-hCG levels and outcome of treatment with methotrexate 
in single dose  regimen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
OUTCOME IN ASSCOCIATION WITH ADNEXAL MASS SIZE  
        Out of 29 patients who were treated with single dose regimen of 
methotrexate, 11 patients had adnexal size less than 2cms where as 18 
had adnexal size more than 2cms. Out of 5 patients who were treated with 
multiple dose regimen, 1 patient had adnexal size less than 2cms, where 
as 4 had adnexal mass more than 2cms. The  outcome in assocociation 
with adnexal mass size is as follows: 
Table 18: Outcome In Asscociation With Adnexal Mass Size 
 Methotrexate regimen 
OUTCOME 
resolved 
% Underwent 
surgery 
% 
Total 
Expectant 
Management Mass Size 
2cm and less 4 80% - - 4 
More than 2cm 1 20% - - 1 
Total 5 - - - 5 
Single Dose 
Regimen Mass Size 
2cm and less 11 38% 0 - 11 
More than 2cm 14 48.2% 4 13.8% 18 
Total 25 - 4 - 29 
Multiple Dose 
Regimen Mass Size 
2cm and less 1 20% 0  1 
More than 2cm 1 20% 3 60% 4 
Total 2 - 3 - 5 
 
P value >0.05, hence no statistical significance was found between 
adnexal mass size and outcome of treatment in single dose regimen and 
multiple dose regimen. 
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OUTCOME IN ASSOCIATION WITH PERIOD OF 
AMENORRHEA 
 Out of 29 patients treated with single dose regimen, 9 patients had 
amenorrhea less than 42 days and 16 presented with amenorrhea more 
than 42 days. Out of 5 patients treated with multiple dose regimen, all 
patients presented with amenorrhea more than 42 days. The outcome of 
treatment in association with period of amenorrhea is as follows: 
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Table 19: Outcome in Association With Period of Amenorrhea 
 
Methotrexate 
regimen Gestational Age 
OUTCOME 
Resolved 
 
 
% 
Underwent 
surgery 
 
 
% Total 
Expectant 
Management 
<42 days 2 40% - - 2 
> 42 days 3 60% - - 3 
Total 5 - - - 5 
Single Dose 
Regimen 
<42 days 9 31% - - 9 
>42 days 16 55.2% 4 13.8% 20 
Total 25 - 4 - 29 
Multiple Dose 
Regimen 
> 42 days 2 40% 3 60% 5 
Total 2 - 3 - 5 
  
 P value >0.05, hence no statistical significance was found between 
period of amenorrhea and outcome of treatment. 
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DISSCUSSION 
This prospective observational study includes all the patients who 
were diagnosed to have unruptured ectopic pregnancy by Transvaginal 
sonography(TVS) and serial beta β-hCG levels, and were managed 
medically with methotrexate. 
 39 patients with unruptured ectopic pregnancy were enrolled in the 
study and were observed for outcome of treatment with methotrexate. 
 The mean age of these 39 patients was 27.3 years ± 5.50 SD.  
Maximum patients belong to 20-29 years i.e.58.9%. The range was 19 to 
36 years. 
 Mean gravidity of the patients studied was 1.74 ± 0.99 SD. 
Maximum patients were primigravidas or second gravidas . 
 Mean gestational age of all patients was 48.2 days ± 9.03 SD. 
Maximum number of patients had gestational age between 6-8 weeks. 
 Out of the 39 patients who were included in this study, 29 were 
managed with single dose regimen, 5 were managed with multiple dose 
regimen, 5 were managed expectantly. 
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Table 20: Unruptured Ectopic Pregnancies (n=39) 
Medical treatment with 
methotrexate 
n=39 
Expectant management 
Single dose 
regimen 
Multiple dose 
regimen 
 
n=5 
n=29 n=5 
 
Expectant management: 
 5 out of 39 patients, who were managed expectantly, were not 
given any dose of methotrexate as the patients did not have any 
symptoms or initial β-hCG levels were very low(<200 m IU/ml). They 
were followed up twice weekly with serial β-hCG measurements and 
weekly by transvaginal ultrasound examinations to ensure a rapidly 
decreasing β-hCG level (ideally <50% of its initial levels within 7 days) 
and a reduction in the size of adnexal mass by seven days. Thereafter, 
weekly β-hCG and transvaginal ultrasound examinations were advised 
until serum β-hCG levels were less than 5 m IU/ml. 
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In the present study, 5 patients were managed expectantly. The 
average initial β-hCG levels in these 5 patients were found to be 177.6 
mIU/ml ± 27.7 SD. The average adnexal mass size at presentation was 
found to be 1.62 cms ± 0.38 SD. The average period of amenorrhea was 
found to be 47 days ± 7.87 SD. These patients were managed as per 
above mentioned protocol and complete resolution was seen in 5 
patients,with an average time for complete resolution being 19.4 days ± 
12.05 SD. 
 
Methotrexate regimen for unruptured ectopic pregnancy 
Single Dose Regimen:  
 Out of 39 patients, 29 patients were given single dose Inj. 
Methotrexate 1mg/kg. 
1. Age: The mean age of these 29 patients was 27.27 yrs ± 5.11 SD. 
Maximum patients belonged to age group of 20 to 29 yrs and the 
range being 20 to 36 years. 
2. Gestational Age: The mean gestational age of these 29 patients 
was found to be 46.3 days ± 8.45 SD. With range between 30 to 65 
days. 
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3. Gravidity : The mean gravidity amongst these 29 patients was 
found to be 1.51. 
4. Β-hCG levels at presentation: The average initial β-hCG levels in 
the patients given with single dose of methotrexate was found to be 
2683.02 m IU/ml. The range was found to be between 400 m IU/ml 
and 6600 m IU/ml. 
5. Outcome of Treatment: 29 patients in this study were given 
single dose of 1mg/kg Inj. Methotrexate intramuscular. However, 
25 responded to medical management with methotrexate without 
any surgical intervention. The end point of treatment i.e. complete 
resolution in these patients mean fall of β-hCG to <5mIU/ml 
without any surgical intervention. 
Remaining 4(13.7%) went for laparotomy before day 7 because    
patients presented with severe abdominal pain or had evidence of 
hemoperitoneum. 
 
Out of the 25 patients treated with methotrexate, 22(76%) resolved 
with single dose of methotrexate, hence successfully managed with single 
dose regimen and remaining 3(10.3%) required repeat second dose of 
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methotrexate on the 7th day due to inadequate fall in β-hCG level (<15%) 
by day 7, when compared to day 4 levels of β-hCG. 
Single Dose Regimen: Outcome of Treatment 
 
 
         
 
 
 
   
 
     
 
Figure: 12 
 
The outcome of recent study was found comparable to the study 
done by Thia EWH et al in K.K Women’s and Children Hospital , 
Singapore during a period of August 2003 to October 2006, who found 
79.1% success rate of single dose of methotrexate (1mg/kg im) given to 
TOTAL NO.OF 
PATIENTS  
      n=29 
SINGLE DOSE OF 
INJ. 
METHOTREXATE 
Img/kg/ml 
RESOLVED WITH 
SINGLE DOSE OF 
METHOTREXATE 
(22)76% 
REQUIRED REPEAT 
SECOND DOSE OF 
METHOTREXATE  
    (3)10.3% 
UNDERWENT 
SURGERY 
    (4)13.7% 
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110 patients presenting with unruptured ectopic pregnancy. 1 patient was 
lost for follow up during this period hence was excluded from the study. 
A similar study done by Mamdoh et al showed a success rate of 
94.3% in 70 patients diagnosed with unruptured ectopic pregnancy. 
 
Table 21: Single Dose Regimen- Outcome of Treatment.  
 
Study (n) 
 
Resolved with 
Single dose 
n(%) 
 
Required 
repeat second 
dose n(%) 
 
Underwent 
surgery n(%) 
 
Thia EWH et 
al(110) 
 
87(79.1) 
 
6(5.4) 
 
16(14.5) 
 
Merisio et al(11) 
 
10(90) 
 
1(10) 
 
- 
 
Mamdoh(70) 
 
66(94.3) 
 
3(4.3) 
 
1(1.4) 
 
Present study(29) 
 
22(76) 
 
3(10.3) 
 
4(13.7) 
 
6. Outcome of Treatment in Association with Initial β-hCG levels 
  Out of the 29 patients treated with single dose methotrexate 
regimen,18 had their initial β-hCG levels <2500 m IU/ml, 4 had their 
initial β-hCG levels between 2500-5000 m IU/ml and 7 had initial β-hCG 
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levels between 5000-7500 m IU/ml. Of these 22(75.7%) patients resolved 
with single dose of methotrexate. However,3(10.3%) patients required 
repeat second dose of methotrexate, 4(13.7%) patients went for 
laparotomy due to inadequate fall in β-hCG levels or persistence 
abdominal pain.  
Statistically significant association was found between initial β-
hCG levels and outcome of treatment. P value < 0.05 significant. 
 
7. Outcome In Association With Adnexal Mass Size: 
Patients presenting with adnexal mass size of less than 2cms i.e 11(38%) 
were successfully treated with single dose regimen and none went for 
laparotomy.Hence success rate of single dose regimen was found to be 38 
% in those having adnexal mass size less than 2cms.  
 Patients presenting with adnexal mass of >2cms i.e.14 (48.2%) 
were successfully treated with single dose regimen, and 4(13.8%) went 
for laparotomy either due to severe abdominal pain or evidence of 
hemoperitoneum. 
No statistical significant association was found between adnexal 
mass size and outcome of treatment (p value > 0.05). 
77 
 
8. Outcome in Association With Period Of Amenorrhea: 
 Of the 9(31%) patients presenting with period of amenorrhea less 
than 42 days, all resolved with single dose regimen -methotrexate 
therapy. None of the patients in this group went for laparotomy. 
 Of the 20(69%) patients presenting with amenorrhea more than 42 
days, 16(55.2%)resolved with methotrexate therapy, 4(13.8) went for 
laparotomy.  
No statistical significant association was found between period of 
amenorrhea and outcome of treatment. (p value > 0.05).  
 
9. Outcome in Association with Cardiac Activity: 
 None of the patients in this study had presence of cardiac activity 
at time of presentation, hence could not be associated with the outcome. 
 
10.Time Taken for Resolution: Average time taken for complete 
resolution of ectopic pregnancy in patients who resolved with single dose 
of methotrexate was found to be 20.44 days ± 7.6 SD. 
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Multiple Dose Regimen for Unruptured Ectopic pregnancies:  
 Out of 39 patients, 5 were treated with multiple doses of Inj. 
Methotrexate 1 mg/kg i.m. 
 
1. Age:  Mean age of these 5 patients was found to be 29.6 yrs ± 7.43 
SD and the range being 21 to 36 yrs. 
2. Gravidity:  The mean gravidity of the patients in multiple dose 
regimen was found to be 2.6. The range was found to be between 1 
and 4. 
3. Gestational Age: The mean gestational age amongst these patients 
was found to be 57.4 days ± 9.68 SD. The range of gestational age 
was between 43 to 70 days. 
4. Initial β-hCG Levels at Presentation:  The mean initial β-hCG 
levels amongst these 5 patients was found to be 7688.4 m IU/ml ± 
5379.9 SD. These patients treated with multiple dose regimen of 
methotrexate had β-hCG levels more than 7500 m IU/ml. 
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5. Outcome of Treatment 
Out of the 5 patients treated with multiple dose regimen, 
2(40%) resolved with methotrexate where as 3(60%) went for 
laparotomy due to persistent abdominal pain or evidence of 
hemoperitoneum. 
 
 
 
                
 
 
 
 
 
 
 
Figure: 13 
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6.Outcome of Treatment in Association with Initial β-hCG levels 
The 5 patients who were treated with multiple dose regimen of 
methotrexate had β-hCG levels >7500 mIU/ml. Out of the 5 patients 
treated with multiple dose regimen, 2(40%) resolved with methotrexate 
where as 3(60%) went for laparotomy due to persistent abdominal pain or 
evidence of hemoperitoneum. The average initial β-hCG levels in these 3 
patients were found to be 9566 m IU/ml. 
 
7. Outcome in Association With Adnexal Mass Size: 
Of the 5 patients in multiple dose regimen, 1(20%) presented with 
adnexal mass size <2cms and treated with multiple dose of methotrexate. 
4(80%) patients presented with adnexal mass size >2cms of which 
3(60%) went for laparotomy due to severe abdominal pain. 
No statistical significant association was found between adnexal 
mass size and outcome of treatment (p value > 0.05). 
8. Outcome in Association With Period Of Amenorrhea: 
 Of the 5 patients treated with multiple doses methotrexate, all 
patients with amenorrhea >42days, 2(40%) patients resolved with 
medical treatment where as 3(60%) required surgical intervention.  
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9. Outcome in association with cardiac activity 
 None of the patients in this study had presence of cardiac activity 
at time of presentation, hence could not be associated with the outcome. 
 
10. Time Taken for Resolution: Mean time of resolution 2 patients out 
of 5 who resolved with multiple doses was 68.5 days ± 40.3 SD. 
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SUMMARY 
• 39 cases of unruptured ectopic pregnancy which were managed 
medically with methotrexate were studied during the period of 
August 2011 to July 2012. 
• Maximum incidence of unruptured ectopic pregnancy was found 
amongst the age group of 20 to 29 years. 
• Commonest risk factor for ectopic pregnancy found in the study 
was Medical Termination of Pregnancy (17.9%), followed by 
previous LSCS being 12.8%. 
• 13% of cases had β-hCG levels <200 m IU/ml, 46.8% of cases of 
unruptured ectopic pregnancies had their initial β-hCG levels 
between 200-2500 m IU/ml, 41.2 % of cases had β-hCG levels 
between 2500-10,000 m IU/ml. 
• 56.4% of cases had adnexal mass size measuring between 2-3cms, 
41% of cases presented with adnexal mass size <2cms, where as 
59% of cases had initial adnexal mass size >2cms. 
• Of the 39 patients studied, 28.2% patients had amenorrhea <42 
days, 56.4% had amenorrhea between 43-56 days, and 15.4% had 
amenorrhea more than 57 days. 
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SINGLE DOSE REGIMEN 
• In cases managed with single dose methotrexate regimen 75.7% 
resolved with methotrexate when the initial β-CG levels were 
<5000 m IU/ml. 13.7% underwent surgery when the initial β-CG 
level >5000 m IU/ml (p value<0.05) significant. 
• None of the cases with adnexal mass size <2cms with single dose 
regimen went for laparotomy where as 13.8% of cases with mass 
size >2cms went for laparotomy. (p value>0.05)not significant. 
• 13.8% of cases with amenorrhea >42 days in single dose 
methotrexate regimen went for laparotomy where as all those with 
amenorrhea <42 days resolved medically (p value>0.05) not 
significant. 
• The association of outcome in relation to presence of cardiac 
activity could not be studied as none of the patients with presence 
of cardiac activity were treated with single dose methotrexate 
regimen. 
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MULTIPLE DOSE REGIMEN 
• In cases managed with multiple dose methotrexate regimen 40% 
resolved with methotrexate when initial β-CG levels were between 
7500-10000 m IU/ml and 60% underwent surgery. 
• None of the cases with adnexal mass <2cms in multiple dose 
regimen went in for laparotomy where as almost 60% of patients 
with adnexal mass >2cms went in for laparotomy(p value>0.05) 
not significant. 
• In cases managed with multiple dose regimen, 40% resolved with 
methotrexate when period of amenorrhea >42days and 60% 
underwent laparotomy when period of amenorrhea was >42days. 
• The association of outcome in relation to presence of cardiac 
activity could not be studied as none of the patients with presence 
of cardiac activity were treated with multiple dose methotrexate 
regimen. 
EXPECTANT MANAGEMENT 
• All patients in expectant management group resolved 
spontaneously, and average initial β-hCG level <200 m IU/ml and 
time of resolution being 19.4 days. 
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CONCLUSION 
• Complete resolution was seen in all cases of single dose 
methotrexate regimen whose mean initial β-hCG was 2683 m 
IU/ml, adnexal mass<2cms and amenorrhea <42days. 
• Statistically significant association was seen between the initial β-
hCG levels and with outcome of treatment. No statistical 
significance was found between adnexal mass size at presentation, 
period of amenorrhea and outcome of treatment in single dose 
regimen. 
• In cases managed with multiple dose methotrexate regimen, 
complete resolution was seen in those having mean initial β-hCG 
of 7688.4 mIU/ml and adnexal mass size <2cms. 
• No statistically significant association was found between adnexal 
mass and outcome of treatment in multiple dose regimen. 
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•  However no association could be assessed between cardiac 
activity and outcome of treatment as none of the patients with 
cardiac activity were treated with methotrexate regimen. 
• However, more studies including more number of patients need to 
be done to assess the correlation between outcome of medical 
management of unruptured ectopic pregnancy with methotrexate 
and initial β-hCG levels, adnexal mass size, and period of 
amenorrhea and presence of cardiac activity. 
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PROFORMA 
 
 NAME:            AGE:            IPNO:          ADDRESS: 
 OCCUPATION:                   DATE OF ADMISSION: 
 DATE OF DISCHARGE: 
 LMP:               GESTATIONAL AGE:               
 ADMISSION:    OPD     CASUALTY      REFERRED 
 
H/O PRESENTING ILLNESS: 
             - PERIOD OF AMENORRHOEA 
             - PAIN ABDOMEN 
             - URINARY COMPLAINTS 
             - BLEEDING/SPOTTING PV  
             - DISCHARGE PV  
             - NAUSEA/ VOMITING 
             - DIARRHOEA 
             - FEVER 
             - CONSTIPATION/ TENESMUS 
 
  
MENSTRUAL HISTORY 
No. of days  
Length of cycle 
RMC/IRMC 
 
Martial History  
           Married for how long, Consanguinity 
           Contraception-OCPs/POPs/IUCD/Barrier/Tubal Sterilization 
    Obstetric History: 
      Gravida,Para,Live,Abortions 
H/O Previous Ectopic 
H/O Tubal Sterlization 
H/O Assisted Reproductive Technique’s 
H/O Previous LSCS 
H/O Hysterosalpingography 
 
Past Medical History: DM/HT/BA/TB/Thyroid 
Disorders/Epilepsy/Heart Disease 
 
  
Past Surgical History: 
Tubal recanalization / hysteroscopy 
Laparoscopy/ D&C 
Abortions 
Any other surgeries 
 
Family History: 
 
On/Examination:  
General condition 
 
Vitals- 
Blood Pressure 
Pulse rate 
Resp. Rate 
Temp. 
  
  
CVS/RS- 
Per Abdomen- 
Tenderness 
Bowel Sounds 
Scars/sinuses 
Previous Scars 
Hernial Orifices 
Per Speculum- 
Per Vaginum- 
Size of Uterus 
Forniceal/cervical motion tenderness 
 
 
 
 
 
 
  
INVESTIGATIONS 
 HEMOGLOBIN, PCV, PT/APTT/INR 
 PLATELETS , TOTAL COUNT , DIFFERENTIAL COUNT, 
LFT, RFT 
 BLOOD GROUPING AND TYPING 
 HBsAg, HIV, VDRL  
 β-HCG LEVELS 
 URINE PREGNANCY TEST 
 TRANSVAGINAL SONOGRAPHY FINDINGS 
      - SAC SIZE 
      - CARDIAC ACTIVITY 
      - FLIUD IN POD 
      - FETAL POLE 
 
 
 
 
 
  
Table 22: Mode of Treatment-single and Multiple Dose Regimen 
Mode of 
treatment 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Single Dose 
MTX 
        
β-HCG 
levels(single dose 
regimen) 
          
Multiple Dose 
MTX 
           
Folinic Acid 
(0.1mg/kg) 
          
β-HCG 
levels(multiple 
dose regimen) 
           
 
Table 23:  Outcome of Treatment in Different Regimens 
Mode of Treatment Outcome 
Expectant 
Management 
Spontaneous Resolution Underwent Surgery 
Single Dose Regimen 
Resolved with 
Single Dose 
Required 
repeat Second 
Dose 
Underwent 
Surgery 
Multiple Dose 
Regimen 
Resolved with 
Methotrexate 
Underwent Surgery 
 
  
PATIENT CONSENT FORM 
STUDY TITLE: A PROSPECTIVE STUDY ON THE OUTCOME OF 
MEDICALLY (METHOTREXATE) MANAGED CASES 
OF UNRUPTURED ECTOPIC TUBAL PREGNANCIES 
AT I.O.G. 
STUDY CENTRE:   Institute of Obstetrics and Gynaecology, Egmore, Chennai. 
PARTCIPANT NAME:  AGE:   I.D.NO: 
 I confirm that I have understood the purpose of the above study. I have the 
opportunity to ask the question and all my questions and doubts have been answered 
to my complete statisfaction. 
  I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving any reason, without my legal rights being 
affected. 
 I understand that investigator, the institution, regulatory authorities and the 
ethics committee will not need my permission to look at my health records both in 
respect to the current study and futher research that may be conducted in relation to it, 
even if I withdraw from the study. I understand that my identity will not be revealed 
in any information released to third parties or published, unless as required under the 
law. I agree not to restrict the use of any data or results that arise from the study. 
 I hereby consent to, undergo complete physical examination, and diagnostic 
tests including haematological , and ultrasonogram examinations for me. 
 I hereby consent to participate in this study on “TO STUDY ON THE 
OUTCOME OF MEDICALLY (METHOTREXATE) MANAGED CASES OF 
UNRUPTURED ECTOPIC TUBAL PREGNANCIES AT INSTITUTE OF 
OBSTETRICS AND GYNAECOLOGY”.  
Place:       Signature of the Patient:  
Date:       Address: 
Signature of the witness:    Signature of Investigator: 
  
S.N
O NAME 
A
GE 
GRAVI
DA 
PA
RA 
LI
VE 
ABORTI
ON 
ECTO
PIC 
GESTATIONA
L AGE 
MASS 
SIZE CA 
MTX 
DOSES 
DAY 1 
HCG 
DAY 3 
HCG 
DAY 4 
HCG 
DAY 5 
HCG 
DAY 7 
HCG 
RESOLUT
ION 
OUTCO
ME 
1 
Vijayalak
shmi 25 2 1 1 0 0 38 1.4 
Ne
g 0 187   74   67 35 Nil 
2 Revathi 22 1 0 0 0 0 48 2.1 
Ne
g 0 130   107   35 28 Nil 
3 Chitra 19 1 0 0 0 0 50 1.25 
Ne
g 0 178   106   97 18 Nil 
4 
Mahesw
ari 21 1 0 0 0 0 56 1 
Ne
g 4 8756 3520   3125 890 97 nil 
5 
Anupreet
hi 32 1 0 0 0 0 48 2.1 
Ne
g 1 1600   1710   750 28 Nil 
6 
Arthi 
banu 22 1 0 0 0 0 43 1.9 
Ne
g 2 5915   5680   5000 50 
2nd 
dose 
7 Lakshmi 28 2 0 0 1 0 56 2.5 
Ne
g 1 476   350   248 10 Nil 
8 Anusha 20 1 0 0 0 0 43 1.9 
Ne
g 2 710   2330   2070 30 
2nd 
dose 
9 Prema 34 1 0 0 0 0 30 2.2 
Ne
g 1 1770   230   200 12 Nil 
10 Praveena 35 4 3 1 0 0 60 3.5 
Ne
g 4 9,780 10,000         Lap 
11 Madhani 29 3 1 1 1 0 58 1.98 
Ne
g 0 197   154   60 7 Nil 
12 Suseela 24 1 0 0 0 0 50 2.5 
Ne
g 1 5390   5400   6000   Lap 
13 Uma 29 1 0 0 0 0 52 2.9 
Ne
g 1 2070   2080   325 10 Nil 
14 Sundari 22 1 0 0 0 0 51 1.65 
Ne
g 1 1370   1800   670 12 Nil 
15 Panjala 34 3 1 1 1 0 58 3 
Ne
g 4 9,890           Lap 
16 llamathy 20 1 0 0 0 0 43 2.65 
Ne
g 1 2530   3500   1100 22 Nil 
17 Vaidagi 22 1 0 0 0 0 43 2.5 
Ne
g 4 9,896 1,130     302.1 40 Neg 
18 Sumithra 25 1 0 0 0 0 51 1.65 
Ne
g 1 1267   1860   670 10 Nil 
19 Kannagi 28 4 2 1 1 0 41 1.4 
Ne
g 0 196 76       9 Neg 
  
20 
Parames
wari 22 3 1 1 0 1 38 2 
Ne
g 1 872.7   560   42.87 17 Neg 
21 Sumathi 25 1 0 0 0 0 44 2.4 
Ne
g 1 6984           Lap 
22 Vani 30 2 1 1 0 0 36 1.5 
Ne
g 1 2618   150   170 23 Nil 
23 Megala 32 3 1 1 1 0 55 2.25 
Ne
g 1 1680   2182   750 28 Nil 
24 Vasanthi 22 1 0 0 0 0 35 1 
Ne
g 1 400   976   200 16 Nil 
25 
Raga 
priya 34 1 0 0 0 0 30 2.3 
Ne
g 1 2010   220   170 23 Nil 
26 Rani 21 1 0 0 0 0 45 2.25 
Ne
g 1 1050   300   200 16 Nil 
27 Selvi 35 2 1 1 0 1 65 2.9 
Ne
g 1 6600   5190   6000   Lap 
28 Vijaya 27 2 1 1 0 0 60 2.35 
Ne
g 1 4185   4300   3275 30 Nil 
29 Premila 36 2 0 0 1 0 48 2.6 
Ne
g 1 980   900   350 26 Nil 
30 Anandhi 33 3 1 1 1 0 41 0.9 
Ne
g 1 1925   3135   2182 30 Nil 
31 
Karpaga
m 36 4 2 1 0 1 70 2.9 
Ne
g 4 9030 9271         Lap 
32 Suganthi 24 1 0 0 0 0 41 2 
Ne
g 1 5390   5400   1080 20 Nil 
33 Kasthuri 31 2 1 1 0 0 41 1.5 
Ne
g 1 2005   1685   882 18 Nil 
34 Malliga 23 1 0 0 0 0 53 1.65 
Ne
g 1 500   400   196 23 Nil 
35 
Mahesw
ari 32 2 1 1 0 0 40 2 
Ne
g 1 5705   5900   1427 26 Nil 
36 Roja 30 2 1 1 0 0 51 2.5 
Ne
g 2 580   1600   1615 28 
2nd 
dose 
37 
Arputha
m 25 1 0 0 0 0 55 2.3 
Ne
g 1 2700   2000   1482 20 Nil 
38 Ragavi 32 2 1 1 0 0 46 2.5 
Ne
g 1 6625   7900   6001   Lap 
39 Sheela 21 1 0 0 0 0 54 1.7 
Ne
g 1 1900   2000   570 26 Nil 
  
KEY TO MASTER CHART 
 
CA  - Cardiac activity 
MTX  - Methotrexate 
β –Hcg -  Beta subunit of human chorionic gonadotropin 
 
  
ABBREVIATION 
ART -  Assisted reproductive techniques 
CI - Confidence interval 
Cms - Centimeters 
DES - Diethylstilbesterol 
EP - Ectopic Pregnancy 
ET - Embryo transfer 
GA - Gestational age 
i.m - Intramuscular 
IUCD - Intrauterine contraceptive device 
IUP    -         Intrauterine pregnancy 
IVF - In vitro fertilization 
LSCS - Lower segment caesarean section 
m IU/ml- Mili International units per Mililiter 
mg/ kg- milligrams per kilograms 
MTP - Medical termination of pregnancy 
MTX - Methotrexate 
PGE2a - Prostaglandin E2 Alpha 
PID - Pelvic inflammatory disease 
POD - Pouch of Douglas 
POP - Progesterone only pills 
RCT - Randomised controlled trial 
Rh - Rhesus factor 
RR - Relative risk factor 
TVS - Transvaginal ultrasonography 
USG - Ultrasonography 
β –hCG-  Beta subunit of human chorionic gonadotropin 
  
 
 
